AI for science · Company
Owkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical development, and (via a spin-out) diagnostics. Its core platform is K Pro, described by Owkin as an AI scientist for biopharma that orchestrates agentic AI skills to reason over multimodal patient data and biological knowledge, with scientists guiding hypotheses and decisions.
Owkin also positions its MOSAIC multimodal oncology dataset and its clinical-research workflows (including a federated/secure approach to patient data access) as key differentiators for producing clinically relevant models and trial decision support. Commercially, Owkin’s approach is largely B2B: it licenses K Pro and its associated data and AI capabilities to pharmaceutical and healthcare organizations and collaborates on programs spanning target discovery, patient subgroup identification, trial optimization (e.g., covariate adjustment / external control arms), and real-world validation. In 2026, Owkin expanded partnership announcements to include new licensing agreements (for example, Servier, Boehringer Ingelheim) and K Pro “agent building” arrangements (for example, AstraZeneca), and it continued to operationalize its agentic infrastructure through integrations and agent releases (including Pathology Explorer via Anthropic’s Claude for Healthcare and Life Sciences).
| Headline | Source | Date |
|---|---|---|
| Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology ResearchOwkin announced an agreement with Servier to license K Pro and multimodal patient data from Owkin’s MOSAIC network for oncology research, positioned as the next chapter in Owkin and Servier’s collaboration. | ||
| Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer IngelheimOwkin announced a licensing agreement with Boehringer Ingelheim for K Pro and multimodal oncology/immunology patient data, describing a prior Boehringer pilot in 2025 and access via K Pro. | ||
| Owkin to Integrate Kognitic's Clinical Trial Data Into K Pro Through New CollaborationOwkin announced a collaboration to integrate Kognitic’s clinical trial data into K Pro, initially targeting oncology and immunology and positioning K Pro as a unified environment for evidence-based agentic workflows. |
| Owkin and Gustave Roussy partner to bring K Pro into real-world clinical practiceOwkin announced a partnership with Gustave Roussy to test K Pro within hospital clinical and research workflows, with an initial focus on molecular tumor boards and multimodal tumor profiling programs. |
| Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement with SanofiOwkin announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, backed by a five-year license for K Pro, and positioned the effort as end-to-end development of AI-driven biopharma a… |
| Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement with AstraZenecaOwkin announced an agreement with AstraZeneca to build biopharma agents as part of AstraZeneca’s three-year licensing of K Pro, describing agent integration within AstraZeneca IT infrastructure and decision workflows. |
| Owkin creates new spin out Waiv, formerly Owkin Dx, with $33m financingOwkin announced the spin-out of Waiv (formerly Owkin Dx) and stated that Waiv will develop AI-powered precision testing, with $33M financing led by OTB Ventures and Alpha Intelligence Capital. |
| Owkin Brings Biology Super Intelligence Closer to Reality with New AI Infrastructure for Biological BreakthroughsOwkin announced launch of its agentic infrastructure for biology and described initial agents such as Pathology Explorer (with stated accuracy/parameter efficiency improvements), including interoperability via Claude for… |